Facebook Twitter YouTube Google Plus

Defactinib, a New Investigational Agent for Mesothelioma

Dr. Joanna C. HorobinThis session was held on April 8 with Dr. Joanna C. Horobin, the Chief Medical Officer at Verastem, Inc. Dr. Horobin discussed the company's latest investigational agent, defactinib, which is being developed for use in patients with pleural mesothelioma.

During the call, Dr. Horobin was interviewed by Mary Hesdorffer, the Meso Foundation’s executive director and experienced nurse practitioner. The session focused on learning more about investigational agent defactinib, which is used to delay the time to progression after having a response or stabilization with first-line therapy.

Dr. Joanna C. Horobin, M.B., Ch.B, has been the Chief Medical Officer at Verastem, Inc. since October 2012.

Listen to more Meet the Mesothelioma Experts podcasts